Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery

Canadian Journal of Physiology and Pharmacology

Volumn 80, Issue 5, 2002, Pages 450-457

  Pham, Dung ^a   Jeng, Arco Y ^a   Plante, Sylvain ^a   Escher, Emanuel ^a   Battistini, Bruno ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Balloon angioplasty; Endothelin; Endothelin converting enzyme; Inhibitors; Neointimal proliferation; Neprilysin; Neutral endopeptidase

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; CGS 25492; CGS 26393; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; GROWTH FACTOR; N [2 (PHOSPHONOMETHYLAMINO) 3 (4 BIPHENYLYL)PROPIONYL] 3 AMINOPROPRIONIC ACID; PRODRUG; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; CAROTID ARTERY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; IC 50; MALE; MORPHOMETRICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RAT; RESTENOSIS;

ANGIOPLASTY, BALLOON; ANIMALS; ASPARTIC ENDOPEPTIDASES; CAROTID ARTERIES; CAROTID STENOSIS; CELL DIVISION; ENZYME INHIBITORS; MALE; METALLOENDOPEPTIDASES; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA;

EID: 0036104285     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y02-059     Document Type: Conference Paper

References (51)

1. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty
2. Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels
3. Endothelin-1 plays a role in the intimal hyperplasia after endothelial removal
4. Blocking of the endothelin system: The development of receptor antagonists
5. Endothelin-converting enzyme inhibitors and their effects
6. Growth regulatory properties of endothelins
7. Endothelins in physiopathology: Circulating plasma levels and presence in other biological fluids
8. Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs
9. Identity of endothelin-converting enzyme and other targets for the therapeutic regulation of endothelin biosynthesis
10. Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: Effect of the ETA receptor antagonist, LU 135252
11. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme
12. Non-peptidic inhibitors of neutral endopeptidase 24.11. 2. Design and pharmacology of orally active phosphonate prodrugs
13. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11
14. Endothelin-1 promotes neointima formation after balloon angioplasty in the rat
15. A role for endogenous endothelin-1 in neointimal formation after carotid artery balloon angioplasty. Protective effect of the novel nonpeptide endothelin receptor antagonist SB 209670
16. A receptor antagonism with BQ-123 is insufficient to inhibit balloon angioplasty-induced neointima formation in the rat
17. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in ballon-injured rat carotid arteries
18. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats
19. C-type natriuretic peptide inhibits intimal thickening after vascular injury
20. Comparison of self-expanding and balloon-expandable stents for the reduction of restenosis
21. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo
22. Purification of a novel endothelin-converting enzyme specific for big endothelin-3
23. Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin
24. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty
25. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
26. Endothelin and restenosis
27. Vein plasma endothelin-1 cyclic GMP increase during coronary angioplasty is related to myocardial ischaemia
28. Neointima formation after vascular injury is angiotensin II mediated
29. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
30. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis
31. Restenosis after successful coronary angioplasty. Pathophysiology and prevention
32. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model
33. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis
34. Experimental models of coronary artery restenosis
35. Modulation of tachykinins and bradykinin by enkephalinase
36. Isolation of an alternative spliced variant of bovine ECE-2
37. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
38. Molecular characterization of endothelin receptors
39. Rat endothelin-converting enzyme-forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11
40. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney
41. Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty
42. The selective endothelin ETA receptor antagonist FR139317 inhibits neointimal thickening in the rat
43. Effect of ET-1 infusion on the development of intimal hyperplasia after balloon catheter injury
44. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11
45. B receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty
46. Isoforms of endothelin-converting enzyme: Why and where?
47. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase)
48. Expression of ET-1, ET-3, ECE-1, and ET-A and ET-B receptor mRNA after angioplasty-induced neointimal formation in the rat
49. Restenosis, the Achilles' heel of coronary angioplasty
50. A novel vasoconstrictor peptide produced by vascular endothelial cells
51. Modulation of endothelin metabolism in guinea-pig tracheal epithelial cells by new dual NEP and ECE peptidase inhibitors